Novo Nordisk (NVO) on Wednesday also launched NovoCare Pharmacy to offer the company’s weight loss drugs for cash-paying ...

Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...

A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...

Adults with obesity who have a prescription for Wegovy but do not have insurance coverage for the drug can now purchase the ...

Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...

A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...

The federal government has spent $6.2 billion on research and development for weight-loss drugs. Now, thanks to Big Pharma ...

Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...

Hims & Hers Health ( HIMS -12.56%) stock took a tumble Thursday morning, falling 9.2% through 11:40 a.m. ET on some ...

Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...